Roy E Smith

Summary

Affiliation: National Surgical Adjuvant Breast and Bowel Project
Country: USA

Publications

  1. ncbi Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58
    Roy E Smith
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    Clin Breast Cancer 3:333-40. 2002
  2. ncbi Chemoprevention of breast cancer and the trials of the National Surgical Adjuvant Breast and Bowel Project and others
    R E Smith
    National Surgical Adjuvant Breast and Bowel Project, Four Allegheny Center, 5th Floor, Pittsburgh, Pennsylvania 15212, USA
    Endocr Relat Cancer 10:347-57. 2003
  3. ncbi Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: review of the literature and the National Surgical Adjuvant Breast and Bowel Project experience
    Roy E Smith
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    Clin Breast Cancer 4:273-9. 2003
  4. ncbi Phase II trial of a doxorubicin/docetaxel doublet for locally advanced and metastatic breast cancer: results from national surgical adjuvant breast and bowel project trial BP-57
    Roy E Smith
    NSABP Foundation, Inc, Pittsburgh, PA 15212, USA
    Clin Breast Cancer 5:208-15. 2004
  5. ncbi Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07
    J Philip Kuebler
    National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Pittsburgh, PA, USA
    J Clin Oncol 25:2198-204. 2007
  6. ncbi Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis
    J Philip Kuebler
    National Surgical Adjuvant Breast and Bowel Project NSABP, Pittsburgh, Pennsylvania 15212, USA
    Cancer 110:1945-50. 2007
  7. ncbi Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27
    Harry D Bear
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    J Clin Oncol 24:2019-27. 2006
  8. ncbi Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06
    Barry C Lembersky
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    J Clin Oncol 24:2059-64. 2006
  9. ncbi Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07
    Stephanie R Land
    National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Pittsburgh, PA 15213, USA
    J Clin Oncol 25:2205-11. 2007
  10. ncbi Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience
    Roy E Smith
    National Surgical Adjuvant Breast and Bowel Project Operations Center, Pittsburgh, PA 15212-5234, USA
    J Clin Oncol 21:1195-204. 2003

Collaborators

Detail Information

Publications14

  1. ncbi Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58
    Roy E Smith
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    Clin Breast Cancer 3:333-40. 2002
    ..6 months (95% CI, 26.6-39.4 months). The administration of ATC with primary ciprofloxacin and secondary colony-stimulating factor prophylaxis is feasible and active. Its value in the adjuvant setting is currently under investigation...
  2. ncbi Chemoprevention of breast cancer and the trials of the National Surgical Adjuvant Breast and Bowel Project and others
    R E Smith
    National Surgical Adjuvant Breast and Bowel Project, Four Allegheny Center, 5th Floor, Pittsburgh, Pennsylvania 15212, USA
    Endocr Relat Cancer 10:347-57. 2003
    ..In addition, future research should focus on the identification of at-risk women who can perhaps be targeted for specific prevention agents...
  3. ncbi Risk for the development of treatment-related acute myelocytic leukemia and myelodysplastic syndrome among patients with breast cancer: review of the literature and the National Surgical Adjuvant Breast and Bowel Project experience
    Roy E Smith
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    Clin Breast Cancer 4:273-9. 2003
    ..In-breast RT appeared to be associated with an increased risk of AML/MDS...
  4. ncbi Phase II trial of a doxorubicin/docetaxel doublet for locally advanced and metastatic breast cancer: results from national surgical adjuvant breast and bowel project trial BP-57
    Roy E Smith
    NSABP Foundation, Inc, Pittsburgh, PA 15212, USA
    Clin Breast Cancer 5:208-15. 2004
    ..1 months. The administration of AT with primary ciprofloxacin and secondary colony-stimulating factor prophylaxis is feasible, and the combination is active. Its value in the adjuvant setting is currently under investigation...
  5. ncbi Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07
    J Philip Kuebler
    National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Pittsburgh, PA, USA
    J Clin Oncol 25:2198-204. 2007
    ..This phase III clinical trial evaluated the impact on disease-free survival (DFS) of adding oxaliplatin to bolus weekly fluorouracil (FU) combined with leucovorin as surgical adjuvant therapy for stage II and III colon cancer...
  6. ncbi Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5-fluorouracil/leucovorin plus or minus oxaliplatin: a prospective analysis
    J Philip Kuebler
    National Surgical Adjuvant Breast and Bowel Project NSABP, Pittsburgh, Pennsylvania 15212, USA
    Cancer 110:1945-50. 2007
    ..Cases of severe gastrointestinal toxicity were monitored prospectively during NSABP C-07, a randomized clinical trial of adjuvant therapy for patients with stage II/III colon cancer...
  7. ncbi Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27
    Harry D Bear
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, USA
    J Clin Oncol 24:2019-27. 2006
    ..This study was designed to determine the effect of adding docetaxel (T) to preoperative doxorubicin and cyclophosphamide (AC) on breast cancer response rates and disease-free survival (DFS) and overall survival (OS)...
  8. ncbi Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06
    Barry C Lembersky
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    J Clin Oncol 24:2059-64. 2006
    ..CONCLUSION: UFT+LV achieved similar DFS and OS when compared with an intravenous, weekly, bolus FU+LV regimen. The two regimens were equitoxic and generally well tolerated...
  9. ncbi Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07
    Stephanie R Land
    National Surgical Adjuvant Breast and Bowel Project Operations Office and Biostatistical Center, Pittsburgh, PA 15213, USA
    J Clin Oncol 25:2205-11. 2007
    ..Definitive analysis revealed an increase in 4-year disease-free survival from 67.0% to 73.2% in favor of FLOX. This study compares neurotoxicity between the treatments...
  10. ncbi Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience
    Roy E Smith
    National Surgical Adjuvant Breast and Bowel Project Operations Center, Pittsburgh, PA 15212-5234, USA
    J Clin Oncol 21:1195-204. 2003
    ..Breast radiotherapy appeared to be associated with an increased risk of AML/MDS...
  11. ncbi Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01
    Roy E Smith
    NSABP Operations Center, Pittsburgh, PA RES, NM NSABP Biostatistical Center, Pittsburgh, PA 15212 5234, USA
    J Natl Cancer Inst 96:1128-32. 2004
    ..We now provide a 10-year update of this trial...
  12. ncbi Pemetrexed/oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program
    James N Atkins
    National Surgical Adjuvant Breast and Bowel Project, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15212, USA
    Clin Colorectal Cancer 5:181-7. 2005
    ..CONCLUSION: This regimen of pemetrexed and oxaliplatin has activity in advanced colorectal cancer, and the toxicity profile suggests that escalation of the dose of pemetrexed in this combination may be possible...
  13. ncbi A review of selective estrogen receptor modulators and national surgical adjuvant breast and bowel project clinical trials
    Roy E Smith
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA 15212, USA
    Semin Oncol 30:4-13. 2003
    ....
  14. ncbi Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial
    Eleftherios P Mamounas
    Aultman Health Foundation, 2600 6th St, SW Canton, OH 44710, USA
    J Clin Oncol 26:1965-71. 2008
    ....